Targeting MCT1 and MCT4 with small-molecule inhibitors has shown promise in disrupting tumor metabolism, though dual inhibition is required to effectively block lactate-driven tumor progression in hypoxic conditions (41, 44). The gene discussed is SLC16A3; the disease is neoplasm.